Delayed Cellular Maturation and Decreased Immunoglobulin κ Light Chain Production In Immature B Lymphocytes Lacking B Cell Linker Protein by Xu, Shengli & Lam, Kong-Peng
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/07/197/10 $5.00
Volume 196, Number 2, July 15, 2002 197–206
http://www.jem.org/cgi/doi/10.1084/jem.20020172
 
197
 
Delayed Cellular Maturation and Decreased Immunoglobulin 
 
 
 
 Light Chain Production In Immature B Lymphocytes 
Lacking B Cell Linker Protein
 
Shengli Xu and Kong-Peng Lam
 
Institute of Molecular and Cell Biology, Singapore 117609, Singapore
 
Abstract
 
B cell linker (BLNK) protein is a component of the B cell receptor (BCR) signaling pathway
and BLNK
 
 
 
/
 
 
 
 mice have a block in B lymphopoiesis at the pro-B/pre-B cell stage. To study
the effect of BLNK mutation at later stages of B cell development, we introduce an innocuous
transgenic BCR into BLNK
 
 
 
/
 
 
 
 mice and show that two populations of immature B cells dis-
tinguishable by their IgM
 
low (lo)
 
 and IgM
 
high (hi)
 
 phenotypes are found in the bone marrow of
these mice in contrast to a single population of IgM
 
hi
 
 cells found in control BCR-transgenic
BLNK
 
 
 
/
 
 
 
 mice. The mutant IgM
 
lo
 
 and IgM
 
hi
 
 cells are at an earlier developmental stage com-
pared with the control IgM
 
hi
 
 cells as indicated by their differential expression of CD43, B220,
and major histocompatibility complex class II antigens and their timing of generation in culture.
Thus, in the absence of BLNK the differentiation of immature B cells is delayed. Furthermore,
mutant IgM
 
lo
 
 cells produce equivalent level of immunoglobulin (Ig) 
 
 
 
 but less Ig 
 
 
 
 proteins
than control and mutant IgM
 
hi
 
 cells and this defect is attributed to a decrease in the amount of
 
 
 
 transcripts being generated. Finally, splenic B cells in BCR-transgenic BLNK
 
 
 
/
 
 
 
 mice are
predominantly of the transitional B cell phenotype and are rapidly lost from the peripheral B
cell pool. Taken together, the data suggest a role for BLNK and perhaps BCR signaling, in the
regulation of 
 
 
 
 light chain expression and continued immature B cell differentiation.
Key words: B lymphocytes • B cell development • B cell receptor • signal transduction • 
adaptor protein
 
Introduction
 
B lymphopoiesis occurs through discrete stages, starting
first from the pro-B and progressing to the pre-B, imma-
ture B and finally, mature B cells. Signal originating from
the pre-B cell receptor (preBCR), and possibly the B cell
receptor (BCR)
 
*
 
 are thought to be required for this highly
regulated process to occur (1). The preBCR is made up of
the Ig heavy chain and the surrogate light chains while the
BCR is composed of the surface Ig, and both forms of the
receptors are complexed to the signal-transducing subunits
Ig
 
 
 
 and Ig
 
 
 
 (2). The importance of the preBCR in B cell
development is evident in gene knockout studies in mice in
which the inactivation of its various components results in
the arrest of B cell differentiation at the very early pro-B
cell stage (1). Although the role of preBCR signaling in
early B cell development is well defined, it is less clear
whether BCR signaling plays a role in the intermediate
stages of B cell maturation other than the maintenance (3)
and activation of mature B cells (2).
BCR signaling has been studied extensively. It is known
that the engagement of the BCR activates various cytoplas-
mic protein tyrosine kinases such as Syk, Lyn, Blk, and
Bruton’s tyrosine kinase (Btk), and this leads ultimately to
the activation of transcription factors such as nuclear factor
of activated T (NF-AT) and NF-
 
 
 
B (4). However, it is not
clear how the activation of the proximal protein tyrosine
kinases is coupled to the activation of the terminal tran-
scription factors, and this in turn is translated into specific
cellular responses such as the activation, proliferation, differ-
entiation, and death of B lymphocytes. Recently, adaptor
proteins with modular domains but no intrinsic enzymatic
activities have been shown to play a major role in BCR
signaling by interfacing tyrosine kinase activation with se-
lective downstream molecules (5). Thus, they may play the
critical role of channeling signaling pathways and directing
specific cellular responses. One such adaptor proteins in B
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lymphocytes is the B cell linker protein (BLNK) (6), which
is also known as SLP-65 (7) or BASH (8). Upon BCR
stimulation, BLNK couples activated Syk to PLC-
 
 
 
, Vav,
Grb2, and Nck (9). In addition, it binds Btk (10, 11) and
is required for the activation of the transcription factor
NF-
 
 
 
B (12).
We and others have generated mice lacking BLNK (13–
16). BLNK
 
 
 
/
 
 
 
 mice have a major block in B cell develop-
ment at the pro-B to pre-B cell stage where the preBCR is
first expressed. This mutant phenotype is consistent with a
role for BLNK in the preBCR signaling of early B lym-
phopoiesis. As few peripheral B cells are generated in
BLNK
 
 
 
/
 
 
 
 mice (13–16), this makes the analysis of the role
of BLNK in the later stages of B cell differentiation diffi-
cult. Although BLNK is known to be involved in the acti-
vation of mature B cells as evidenced by the inability of
BLNK
 
 
 
/
 
 
 
 mice to respond to a T cell–independent anti-
gen (13), its role (if any) in regulating some aspects of B cell
physiology at the immature B cell stage is less clear. Thus,
to further examine the role of BLNK in the intermediate
stage of B cell differentiation, we now introduced an in-
nocuous transgenic BCR into BLNK
 
 
 
/
 
 
 
 mice.
 
Materials and Methods
 
Mice.
 
BLNK
 
 
 
/
 
 
 
 (13), B1–8H/
 
 
 
 (3) and 3–83
 
 
 
/
 
 
 
 (17) mice
had been reported previously. All mice were bred and used at
6–8 wk of age according to institutional guidelines.
 
Cell Preparation and Culture.
 
Bone marrow cells were ob-
tained by injecting PBS containing 3% FCS and 0.1% NaN
 
3
 
 into
the femurs and tibia of mice. Splenic cells were obtained by disso-
ciating the tissue with a plastic mesh and rubber-stopper from a
5-ml syringe. All cells were treated with red blood cell lysing so-
lution (0.15 M NH
 
4
 
Cl, 1 mM KHCO
 
3
 
, and 0.1 mM Na
 
2
 
EDTA)
to eliminate erythrocytes. For cell culture experiments, IgM
 
 
 
cells were removed from bone marrow samples using anti-IgM
mAb-coupled MACS beads (Miltenyi Biotec) in a negative selec-
tion protocol. The postselected bone marrow cells were cultured
in RPMI 1640 supplemented with 10% FCS. In some experi-
ments, cells were cultured for 48 h in the presence of chemical
inhibitors (Calbiochem) of signaling molecules. The inhibitors
and the range of concentrations used are: BAPTA/AM (10–50
 
 
 
M); EGTA (0.75–500 
 
 
 
M); SN50 (18–36 
 
 
 
M); PD98059 (20–
100 
 
 
 
M); LY294002 (2–10 
 
 
 
M) and PP2 (50–200 
 
 
 
M).
 
Flow Cytometry.
 
For FACS
 
®
 
 analyses, cells were stained with
optimal amounts of FITC-, PE-, and biotin-conjugated mAbs for
10 min on ice and washed twice with PBS. Biotin-conjugated
mAbs were revealed with Streptavidin-CyChrome. For
intracellular staining, cells were fixed in 2% PBS-buffered para-
formaldehyde for 20 min at 4
 
 
 
C, washed, and stained with either
anti-
 
 
 
 or anti-
 
 
 
 mAb for 20 min in PBS containing 0.5% sapo-
nin (Sigma-Aldrich). FACS
 
®
 
 analyses were performed on a FAC-
Scan™ (Becton Dickinson) using CELLQuest™ software. The
following mAbs were obtained from BD PharMingen: anti-IgM
(R6–60.2), anti-B220 (RA3–6B2), anti-CD21 (7G6), anti-CD24
(HSA), anti-CD43 (S7), anti-
 
 
 
 (R5–240), anti-
 
 
 
 (LS136), and
anti-MHC class II (2G9). The Ac146 anti-idiotypic antibody was
obtained from Dr. K. Rajewsky (Harvard Medical School, Bos-
ton, MA).
 
5-Bromo-2-Deoxyuridine Incorporation Studies.
 
To study the rate
of turnover of peripheral B cells, mice were fed continuously
 
with water containing 1 mg/ml of 5-bromo-2-deoxyuridine
(BrdU) over a 1-wk period. Cells were recovered from the ani-
mals and stained with anti-B220 and anti-IgM antibodies to iden-
tify B cells and later fixed for 30 min in 1 ml ice-cold 70% etha-
nol and overnight in PBS containing 2% paraformaldehyde and
0.02% Tween-20. Thereafter, cells were washed once in PBS and
incubated for 10 min at room temperature in a solution contain-
ing 150 mM MgCl
 
2
 
, 10 
 
 
 
M HCl, and 300 
 
 
 
g/ml Dnase 1. Fi-
nally, cells were stained intracellularly with anti-BrdU antibody
(Becton Dickinson) for 20 min at room temperature, washed
twice in PBS, and analyzed on a FACScan™.
 
Semiquantitative Reverse Transcription PCR Analysis of 
 
 
 
 Expres-
sion.
 
Bone marrow IgM
 
 
 
 cells from BCR transgenic BLNK
 
 
 
/
 
 
 
mice were purified via positive selection using anti-IgM mAb-
coupled MACS beads (Miltenyi Biotec). IgM
 
lo
 
 and IgM
 
hi
 
 cells
from TG1 BLNK
 
 
 
/
 
 
 
 mice were FACS
 
®
 
-sorted using anti-IgM
and anti-B220 mAbs. The purity of the cell population obtained
as assessed by FACS
 
®
 
 is 
 
 
 
90%. Total RNA was extracted from
5 
 
 
 
 10
 
5
 
 cells with TRIZOL reagent (GIBCO BRL) and reverse
transcribed into cDNA in a reaction of 20 
 
 
 
l using the Superscript
Preamplification System (GIBCO BRL). The following primers
were used in the amplification: the constant region of immuno-
globulin 
 
 
 
 heavy chain (C
 
 
 
1: 5
 
 
 
-GTCTGATAAGAATCTG-
GTGGCC-3
 
 
 
, C
 
 
 
2: 5
 
 
 
-TTCTTCAAGAAGGTGAGACCCC-
3
 
 
 
); constant region of 
 
 
 
 light chain (C
 
 
 
1: 5
 
 
 
-ATGCTGCAC-
CAACTGTATCC-3
 
 
 
, C
 
 
 
 2: 5
 
 
 
-GTTGAAGCTCTTGA-
CAATGGG-3
 
 
 
); and the control G protein 
 
 
 
 subunit (G
 
 
 
S)
(G
 
 
 
S1: 5
 
 
 
-ATTGAAACCATTGTGGCCGCCATGAGC-3
 
 
 
,
G
 
 
 
S2: 5
 
 
 
-GAAGACACGGCGGATGTTCTCAGTGTC-3
 
 
 
).
Reverse transcription (RT)-PCR was performed in a 50-
 
 
 
l reac-
tion mixture that contained 1 
 
 
 
l of threefold serially diluted
cDNA template. PCR was performed at 94
 
 
 
C for 1 min, 60
 
 
 
C for
1 min, and 72
 
 
 
C for 1 min for a total of 40 cycles. RT-PCR
products were loaded onto 1.2% agarose gel and visualized by
Southern blotting using specific radioactive probes.
 
Results
 
Appearance of IgM
 
lo
 
 Cells in the Bone Marrow of BLNK
 
 
 
/
 
 
 
Mice Expressing an Innocuous Transgenic BCR.
 
Mice lack-
ing the adaptor protein BLNK have a major block in B cell
development at the pro-B to pre-B cell transition stage
where the preBCR is first expressed (13–16). This devel-
opmental stage arrest is likely due to defective signaling by
the preBCR in the absence of BLNK. However, the im-
pairment in B cell differentiation in BLNK
 
 
 
/
 
 
 
 mice is not
absolute as some peripheral B cells are generated (13–16)
and the reason for this leakiness is unknown. To determine
if the expression of a transgenic BCR can bypass the early
developmental block in BLNK
 
 
 
/
 
 
 
 mice, we crossed wild-
type and BLNK
 
 
 
/
 
 
 
 mice with mice bearing the V
 
H
 
B1–8
VDJ and V
 
 
 
3–83 VJ gene segments that were inserted by
gene-targeting into the physiological Ig heavy (H) and light
(L) chain loci, respectively (3, 17). The resulting BLNK
 
 
 
/ 
mice bearing the VHB1–8/V 3–83 BCR are designated as
TG1 BLNK /  mice. The VHB1–8 gene segment was
derived from an antibody directed against the hapten
4-hydroxy-3-nitrophenyl acetyl (18) while the V 3–83
gene segment was derived from an anti-H-2b antibody
(19). However, the VHB1–8/V 3–83 BCR is of unknown
but innocuous specificity (20). Mice bearing single alleles of199 Xu et al.
VHB1–8 and V 3–83 are used in all subsequent experi-
ments to ensure that the level of expression of the trans-
genic H and L chains is physiological and mimics that of
the   and   proteins found in normal mice.
As shown in Fig. 1 A, wild-type mice have a distinct
population of B220 IgM  pre-B cells in their bone mar-
row in addition to a population of immature B cells that
express a continuum level of IgM on their cell surfaces
(Fig. 1 A, top panel). In contrast, BLNK /  mice have few
immature B cells as B cell development in these mice is ar-
rested at the pro-B/pre-B cell stage (13–16). On the other
hand, BLNK /  B cells that express the transgenic VHB1–
8/V 3–83 BCR can bypass the pre-B cell stage of develop-
ment and directly differentiate into IgMhigh (hi) immature B
cells (Fig. 1 A, third panel). This is in agreement with pre-
viously published data (20) and is not surprising as the
pre-B cell stage is where the rearrangement of L chain gene
segments takes place but these transgenic B cells already
possessed and expressed a functional L chain knock-in V
region gene segment and thus exhibited expedited devel-
opment. The IgMhi phenotype of immature B cells found
in these mice probably reflects the development of a mono-
clonal population of B cells in contrast to the development
of a polyclonal B cell population in wild-type mice. Inter-
estingly, BLNK /  mice bearing the VHB1–8/V 3–83
BCR generate a larger fraction of IgM  cells ( 2–3-fold)
in their bone marrow compared with BLNK /  mice
bearing the same transgenic BCR. Moreover, two distinct
B cell populations are evident in the bone marrow of TG1
BLNK /  mice (Fig. 1 A, fourth panel). In addition to the
IgMhi population that is seen in the TG1 BLNK /  mice,
TG1 BLNK /  mice also have an IgMlow (lo) B cell popula-
tion. The presence of this population of B cells that ex-
presses lower level of BCR on the cell surface is also con-
firmed by anti-  staining (Fig. 1 B, top panel).
As BLNK is directly involved in BCR signaling (6), it is
conceivable that the presence of this IgMlo B cell popula-
tion in TG1 BLNK /  mice is indicative of the occurrence
of some form of receptor editing. Our previous finding that
BLNK-deficient B cells maintain intact allelic exclusion of
the Ig loci (21) suggests that this is unlikely the case. How-
ever, to definitively rule out this possibility, we stained for
Ig -expressing cells in TG1 BLNK /  mice. It has been
shown previously that as a consequence of receptor editing,
there is an increase in the population of Ig -expressing B
cells in autoreactive BCR transgenic mice (22). However,
FACS® analyses of bone marrow (Fig. 1 B, bottom panel)
or splenic (data not shown) B cells indicate that only a small
fraction of the B cells express the   L chain in TG1
BLNK /  mice and this is comparable to the fraction
found in TG1 BLNK /  mice. Furthermore, staining of B
cells with the anti-idiotypic mAb Ac146, which recognizes
the VHB1–8/V 3–83 combination, indicates that virtually
all the B cells in the spleen (Fig. 1 C) and bone marrow
(data not shown) of TG1 BLNK /  mice express the
knock-in H and L chains. Taken together, the data suggest
that there is no evidence of receptor editing occurring in
TG1 BLNK /  mice.
Thus, the data suggest that the introduction of an innoc-
uous transgenic BCR can bypass the early developmental
block in BLNK /  mice and leads to the generation of a
large population of IgM  cells in their bone marrow.
Figure 1. B cell development
in BLNK /  mice bearing an
innocuous knock-in BCR.
FACS® analysis of bone marrow
B cells in wild-type and
BLNK /  as well as BCR trans-
genic BLNK /  and BLNK / 
mice bearing a knock-in VHB1–
8/V 3–83 BCR (TG1). Mice
used are heterozygous with re-
spect to the knock-in Ig heavy
and light chain alleles. The bone
marrow samples were stained for
(A) B220 and IgM, and (B) B220
and Ig - or Ig -expressing cells.
(C) Splenic B cells from wild-
type, TG1 BLNK / , and TG1
BLNK /  mice were analyzed
for the expression of the VHB1–
8/V 3–83 idiotype using the
anti-Ac146 Ab. Numbers indi-
cate percentage of total cells and
the figure shown is representa-
tive of five independent analyses.200 BCR Signaling During Immature B Cell Differentiation
However, a substantial fraction of these cells ( 50%) is of
the IgMlo phenotype and appears to represent cells in an as
yet undefined stage of differentiation.
Delayed Cellular Maturation of IgM  Cells in TG1
BLNK /  Mice. To gain insight into the population of
IgMlo cells in TG1 BLNK /  mice, we analyze these cells
with respect to a series of maturation markers. As shown in
Fig. 2, TG1 BLNK /  B cells express high levels of the
pan-B cell marker B220 and high levels of the heat stable
antigen CD24 but low levels of CD43 on their cell sur-
faces. Thus, they resemble immature B cells found in nor-
mal mice. Interestingly, both the IgMhi and IgMlo cells in
TG1 BLNK /  B cells express lower levels of B220 and
CD24 but higher levels of CD43 on their cell surfaces sug-
gesting that they resemble more of the pro-B/pre-B than
the immature B cell phenotype (23). On closer examina-
tion, the level of CD43 expression on the mutant IgMlo
cells is even higher than that found on the mutant IgMhi
cells. Thus, the IgMlo and IgMhi cells in TG1 BLNK / 
mice appear to be less “mature” than the IgM  cells found
in TG1 BLNK /  mice.
To confirm this observation, we stained the cells with
anti-MHC class II antibodies. The expression of the MHC
class II antigens is regulated during B lymphopoiesis such
that there is a progressive increase in their expression from
the pre-B cell stage onwards with a higher level of expres-
sion on immature and mature B cells (24–26). Indeed,
FACS® analyses indicate that both the IgMlo and IgMhi
cells in TG1 BLNK /  mice express significantly lower
levels of MHC class II antigens on their cell surfaces com-
pared with the IgM  cells in TG1 BLNK /  mice (Fig.
2). In addition, the level of MHC class II antigens on mu-
tant IgMlo cells is even lower than that found on mutant
IgMhi cells. Thus, the FACS® analyses suggest that the im-
mature B cells in TG1 BLNK /  mice are at an earlier dif-
ferentiation stage compared with the immature B cells in
TG1 BLNK /  mice, and furthermore that the mutant
IgMlo cells may be even less differentiated than the mutant
IgMhi cells.
As the mutant IgMlo and IgMhi cells are relatively imma-
ture compared with the control BLNK / IgM  cells, we
decided to examine the cell cycle status of these cells. How-
ever, analysis of the intracellular DNA content of wild-type
IgM  and mutant IgMlo and IgMhi cells by 7-AAD staining
revealed no significant differences among these cells and
that they are all noncycling (data not shown).
To further distinguish between the differentiation of
IgMlo and IgMhi cells in TG1 BLNK /  mice, we purified
and cultured bone marrow B220 IgM  cells for various
times. As seen in Fig. 3, B220 IgM  cells from control
TG1 BLNK /  mice give rise mainly to IgMhi cells after
16–24 h of culture and the same population of cells is re-
covered even after the 72 h time point. In contrast,
B220 IgM  cells from TG1 BLNK /  mice generate
mainly IgMlo cells after 16–24 h in culture. However, an
increasing fraction of IgMhi cells is recovered at the 48–72 h
time points. This, together with the in vivo staining data
(Fig. 2), suggest that the IgMlo cells likely arise before the
IgMhi cells in TG1 BLNK /  mice. Taken together, the
overall data indicate that the absence of BLNK appears to
delay the maturation of developing B cells in the bone
marrow.
Decreased Intracellular   Light Chain Expression in IgMlo
Cells of TG1 BLNK /  Mice. We next examined the rea-
son for the lower level of BCR expression on IgMlo cells in
the bone marrow of TG1 BLNK /  mice. It is possible
that these cells produce lesser amount of   and/or   pro-
teins or alternatively, these IgMlo cells could produce equal
amount of cytoplasmic   and   proteins as the IgMhi cells
but they express lower levels of IgM on their cell surfaces.
To distinguish between these possibilities, we stain for in-
tracellular   and   proteins in the IgM  cells of both TG1
BLNK /  and TG1 BLNK /  mice. As shown in Fig. 4,
the IgMhi cells in TG1 BLNK /  mice have equivalent
amount of cytoplasmic   and   compared with the IgMhi
cells in TG1 BLNK /  mice. Interestingly, the IgMlo cells
in TG1 BLNK /  mice produce equivalent amounts of  
but much lesser amounts of   compared with the IgMhi
Figure 2. Phenotypic analysis
of IgM  cells in the bone marrow
of TG1 BLNK /  mice. Bone
marrow cells from TG1
BLNK /  and TG1 BLNK / 
were stained with anti-B220 and
anti-IgM and with either anti-
CD43, anti-CD24, or anti-
MHC class II mAbs. Figure
shown is representative of four
independent analyses.201 Xu et al.
cells in TG1 BLNK /  or BLNK /  mice. This indicates
that the lower levels of surface BCR expression on IgMlo
cells is likely due to the decreased production of   proteins.
The decrease in the production of   light chain proteins
in the IgMlo cells could be due to a decrease in the genera-
tion of the   transcripts or in their translation into pro-
teins. If the latter were the reason, then equivalent amount
of transcripts should be found in the cells of TG1 BLNK / 
and TG1 BLNK /  mice. To examine these possibili-
ties, we isolated RNA from equal number of purified
IgM  cells from TG1 BLNK /  and IgMlo and IgMhi cells
from TG1 BLNK /  mice and subject them to RT-PCR
analyses. As shown in Fig. 5, semiquantitative RT-PCR
analyses of serially diluted samples indicate that compared
with the IgM  cells from TG1 BLNK /  mice, much less
  transcripts are found in both IgMhi and IgMlo cells of
TG1 BLNK /  mice and with the mutant IgMlo cells hav-
ing even much lesser   transcripts compared with the mu-
tant IgMhi cells. As control and consistent with the intra-
cellular   staining data (Fig. 4), equivalent amounts of  
transcripts is found in all three samples. Hence, the data
suggest that the decrease in   protein in the mutant IgMlo
cells is likely due to a decrease in the amount of transcripts
being generated.
Surface IgM Expression Levels on Differentiating B Cells Can
Be Modulated by Inhibitors of Signaling Proteins. As BLNK
is an adaptor protein in BCR signal transduction (6) and is
known to activate numerous signaling pathways (6–12), we
decided to investigate the signaling pathways that might be
involved in signaling   expression. The small number of B
cells in the bone marrow makes it difficult for us to obtain
enough cells from either TG1 BLNK /  or TG1 BLNK / 
mice for Western blot analysis of biochemical pathways.
Besides, low level basal signaling in the absence of deliber-
ate BCR stimulation may not be detectable using this con-
ventional methodology. Last but not least, it is impossible
for us to isolate mutant IgMhi and IgMlo cells from TG1
Figure 3. In vitro culture of
Ig-negative bone marrow cells
from TG1 BLNK /  mice. Bone
marrow cells were depleted of
IgM  cells using anti-IgM mAb-
coupled magnetic beads before
culture. Cells were stained with
anti-B220 and anti-Ig  mAb at
the 0 h time point to determine
the purity of the cells and with
anti-B220 and anti-IgM mAbs to
examine the differentiation of the
cells at various time points in cul-
ture. Figure shown is representa-
tive of five independent analyses.
Numbers indicate percentage of
total IgM  cells.
Figure 4. Expression levels of intracellular   and   proteins in IgM 
cells from TG1 BLNK /  and IgMhi and IgMlo cells from TG1 BLNK / 
mice. Bone marrow cells obtained from TG1 BLNK /  and TG1
BLNK /  mice were stained for the extracellular expression of B220 and
IgM and the intracellular expression of   and   via FACS®. Figure shown
is representative of five independent analyses. Abs used are FITC-anti-
IgM, PE-anti-B220 for the extracellular staining, and bio-anti-IgM or
bio-anti-Ig  for the intracellular staining, the latter two of which are re-
vealed with streptavidin-Cychrome.
Figure 5. Semiquantitative RT-PCR analysis of   and   RNA tran-
scripts in bone marrow IgM  cells of TG1 BLNK /  and IgMhi and IgMlo
cells of TG1 BLNK /  mice. Bone marrow IgM  cells from TG1
BLNK /  mice were purified via positive selection using anti-IgM–cou-
pled magnetic beads while IgMhi and IgMlo cells from TG1 BLNK / 
mice were FACS® sorted. The purity of cells obtained is  90%. RNA is
prepared from equal numbers of purified cells and reverse transcribed into
cDNA. The cDNA template is serially diluted threefold and subjected to
PCR analyses to detect the expression level of   and   transcripts. G S
expression is used as a control for the amount of cDNA template used.202 BCR Signaling During Immature B Cell Differentiation
BLNK /  mice without stimulating their BCR, as we will
have to FACS-sort these cells using fluorochrome-coupled
anti-IgM antibodies to identify their phenotype.
We thus employed the alternative method of blocking
specific signaling pathways using chemical inhibitors. Bone
marrow cells depleted of IgM  cells from TG1 BLNK / 
mice were cultured for 48 h in the presence of varying
concentrations of various inhibitors and developing B cells
were analyzed for their cell surface expression of IgM. As
can be seen in Fig. 6 A, disruption of calcium signaling us-
ing calcium chelators such as EGTA at 0.75–500  M or
BAPTA/AM at 10–50  M did not affect the level of sur-
face IgM expression on B cells. Similarly, inhibiting the
NF- B pathway using SN50 (18–36  M) or the extra-
cellular signal–regulated kinase (ERK) pathway using
PD98059 (20–100  M) did not lead to a lower level of
surface IgM expression. On the other hand, B cells that dif-
ferentiated in the presence of LY294002 (2–10  M) that
inhibits the activation of PI3K or PP2 (50–200  M) that
inhibits src-family tyrosine kinases did have much lower
expression of surface IgM. Moreover, the decrease in sur-
face IgM expression on B cells in the presence of
LY294002 or PP2 is dosage dependent (data not shown).
Finally, as shown in Fig. 6 B, B cells differentiating in the
presence of LY294002 or PP2 but not BAPTA/AM and
PD98059 also have a lesser amount of intracellular   pro-
teins. Thus, it appears that a signaling pathway involving
Src-family kinase, PI3K, and BLNK is involved in signaling
  light chain expression in B cells.
Splenic B Lymphocytes in TG1 BLNK /  Mice Are Pre-
dominantly Early Stage Transitional B Cells. As seen in Figs.
1 and 7, the introduction of a transgenic BCR leads to a
greater than twofold increase in the number of IgM  (IgMlo
and IgMhi) cells in the bone marrow of TG1 BLNK / 
mice compared with control animals. This suggests that the
expression of a transgenic BCR can bypass the develop-
mental block in BLNK /  mice. However, such an accu-
mulation of B cells is not apparent in the peripheral lym-
phoid tissues of these mice. Instead, there is a two- to
threefold reduction in the number of B cells in the spleen
of TG1 BLNK /  mice compared with the control animals
(Fig. 7). This suggests that BLNK deficiency may also per-
turb the further differentiation of peripheral B cells.
Given the finding that the B cells in the bone marrow of
TG1 BLNK /  mice are at an earlier differentiation stage
compared with those in control mice, we next examined
the differentiation of the B cells in the peripheral lymphoid
tissues of TG1 BLNK /  mice. Previously, we have shown
that the peripheral B cells in BLNK /  mice do not differ-
entiate into the mature IgMloIgDhi fraction (13). Consistent
with that observation, the splenic B cells in TG1 BLNK / 
mice are mainly of the IgMhi transitional B cell phenotype
(Fig. 8). In addition, we now show that a large fraction of
these cells express low level of the MHC class II antigens
on their cell surfaces in contrast to the high level expression
Figure 6. Expression level of surface IgM and intracellular   on differ-
entiating bone marrow B cells from TG1 BLNK /  mice cultured in the
presence of chemical inhibitors of signaling molecules. Bone marrow cells
depleted of B220 IgM  cells from TG1 BLNK /  mice were cultured in
the presence of various inhibitors for 48 h. Differentiating B220  B cells
were analyzed for their expression level of surface IgM (A); and intracellu-
lar level of   (B) via FACS®. B cells from TG1 BLNK /  and TG1
BLNK /  B cells cultured in medium alone or in the presence of 0.1%
DMSO that was used to dissolve some of the chemical inhibitors are used
as controls. Figure shown is representative of three independent analyses.
Figure 7. Number of B cells in the bone marrow and spleen of TG1
BLNK /  and BLNK /  mice. Comparison of the number of IgM  cells
in the bone marrow (two hind limbs) and spleen of TG1 BLNK / 
(white circle) and TG1 BLNK /  (black circle) mice. Each circle repre-
sents a single animal. Calculation of the number of B cells is based on total
cell count and the percent of B220 IgM  cells as assayed by FACS®
staining. Statistical significance is determined by a paired two-tailed Stu-
dent’s t test.203 Xu et al.
of these antigens on splenic B cells found in the control
TG1 BLNK /  mice. Similarly, a large fraction of the
splenic B cells in TG1 BLNK /  mice are also CD43 
compared with the cells found in control mice. These
CD43  splenic B cells are not B-1 cells, as the CD5  B cell
subset is not found in BLNK /  mice (13–16). These data
would again suggest that the splenic B cells in TG1
BLNK /  mice are less mature compared with those found
in the spleen of control mice.
To determine the precise stage in which BLNK defi-
ciency affects B cell differentiation in the periphery, we ex-
amined in detail the transitional B cell population in TG1
BLNK /  mice. Transitional (T) B cells can be further re-
solved into the earlier T1 and the later T2 cell stages on the
basis of CD21 expression (27, 28). T1 cells are IgMhiCD2llo
while T2 cells are IgMhiCD21hi and mature B cells are
IgMintermediate (int) CD21int. As shown in Fig. 8, the splenic B
cells in TG1 BLNK /  mice are predominantly T1 cells,
suggesting that in the absence of BLNK, the cells failed to
develop into the T2 cell stage.
As B cells in TG1 BLNK /  mice are arrested at the
transitional T1 cell stage, they are likely to be short-lived
(27) and not selected into the long-lived mature B cell pool
(29). Indeed, one would expect a higher rate of turnover of
peripheral B cells in the mutant mice, and this might ac-
count for the loss of cells in these animals. To determine if
this is the case, we examine the rate of turnover of the pe-
ripheral B cells in the mutant mice. TG1 BLNK /  and
TG1 BLNK /  mice were fed with BrdU in drinking wa-
ter and the fraction of splenic B cells that had incorporated
BrdU over a 1-wk period was determined. As shown in
Fig. 9, the fraction of IgM  B cells that had incorporated
BrdU in the mutant mice is approximately twice that of the
wild-type mice, suggesting that there is a greater loss of pe-
ripheral B cells in the absence of BLNK.
Discussion
BLNK /  mice have a major block in B cell develop-
ment at the pro-B/pre-B cell stage and few peripheral B
cells are generated (13–16). This makes the analysis of the
role of BLNK in the later stages of B cell development dif-
ficult. We show here that the introduction of an innocuous
transgenic BCR into BLNK /  mice leads to the genera-
tion of a large population of IgM  cells in the bone mar-
row and thus could circumvent the problem. Our data fur-
ther indicate that BLNK plays a role in the intermediate
stages of B cell differentiation, in particular at the immature
and transitional B cell stages. BLNK /  mice bearing an in-
nocuous transgenic BCR develop two populations of im-
mature B cells in their bone marrow that is distinguishable
by their surface IgM expression level (Fig. 1). The IgMlo
cells in these mutant mice are apparently at an earlier devel-
opmental stage compared with the IgMhi cells and both
these cell populations are less “mature” than the immature
IgMhi cells found in control BLNK /  mice bearing the
same transgenic BCR (Fig. 2). Furthermore, the IgMlo cells
in BCR transgenic BLNK /  mice express less Ig   light
chain proteins compared with the IgMhi cells in both
BLNK /  and BLNK /  mice (Figs. 4 and 5). Thus, in the
absence of BLNK the production of   light chain is de-
creased and the cellular maturation of developing B cells is
delayed. In addition, BLNK also play a role in the further
differentiation of B cells in the periphery (Fig. 8) as almost
all the peripheral B cells in the mutant mice are transitional
stage 1 (T1) cells.
B cell development occurs in discrete stages and the role
of preBCR signaling in driving B lymphopoiesis is well
documented as the inactivation of various signaling mole-
cules such as Ig  (30), Btk (31, 32), and BLNK (13–16) all
lead to an arrest of B cell development at the pro-B cell
Figure 8. Phenotypic analysis of splenic B cells in TG1 BLNK / 
mice. Spleen cells from TG1 BLNK /  and TG1 BLNK /  mice were
stained with anti-B220 and anti-IgM and with either anti-MHC class II
or anti-CD43 mAbs (top three panels). Transitional (T) stage 1 and 2 and
mature (M) B cells are resolved using anti-IgM and anti-CD21 mAbs
(bottom panel). Figure shown is representative of five independent analy-
ses. Numbers indicate percent of total cells.
Figure 9. Turnover of splenic
B cells in TG1 BLNK /  mice.
Groups of five TG1 BLNK / 
and TG1 BLNK /  mice were
continuously fed with BrdU in
drinking water for a period of 1
wk and splenic B220 IgM  cells
were stained for their intracellu-
lar BrdU content. Statistical sig-
nificance is determined by a
paired two-tailed Student’s t test.204 BCR Signaling During Immature B Cell Differentiation
stage. In addition, mice with mutations in the cytoplasmic
regions of Ig  (33) or Ig  (34) have impairment in the
generation of immature B cells. However, it is less clear
whether BCR signaling is required for continued B cell
differentiation at the immature B cell stage other than for
the maintenance (3) and activation (2) of mature B cells. In
particular, it is not known whether the assembly and ex-
pression of a functional BCR per se is sufficient for imma-
ture B cell development or that its signaling is also re-
quired. Our current data from the TG1 BLNK /  mice
would suggest the latter since BLNK is an adaptor protein
in the BCR signal transduction pathway.
The data presented here suggest that the BCR, upon as-
sembly and presumably initial low level expression on the
cell surface, can signal its own increased expression by reg-
ulating the transcription of the Ig light chain. Apparently,
in the absence of BLNK, basal BCR signaling is perturbed
and this leads initially to a decrease in Ig   production and
subsequently results in the generation of a population of
IgMlo cells in the mutant mice. Later, as the   transcripts and
protein accumulate, the cells then acquire the IgMhi phe-
notype. In addition, as a consequence of continued impair-
ment in BCR signaling due to the absence of BLNK, the
IgMlo mutant cells did not down-regulate CD43 and up-
regulate B220 and MHC class II antigens. Gradual changes
to these cell surface antigens and hence further differentia-
tion occur only after the mutant cells acquire the IgMhi
phenotype but the change is still delayed compared with
the control IgMhi cells, presumably due to a weaken signal.
This would suggest that the strength of the BCR signaling
is the determining factor in the further differentiation of
immature B cells. A weak signal leads to a delay in the mat-
uration of developing B cells (this paper) while excessive
BCR signaling leads to their deletion as in the case of au-
toreactive B cells (19). It remains to be determined
whether BCR signaling directly regulates the expression
level of some of the antigens associated with the differenti-
ation of B cells, in particular the MHC class II antigens.
This is particularly interesting as the expression level of
MHC class II antigens correlates with the expression level
of IgM on BCR transgenic BLNK /  cells (Fig. 2) and
furthermore, their level is decreased upon the induced de-
letion of BCR on mature B cells (3).
BLNK is a central molecule in the BCR signaling path-
way (6) and is involved in the activation of Rac-JNK (9),
Vav and Nck (6), and NF- B (12) signaling. Hence, it re-
mains to be determined if any of these molecules and path-
ways are also involved in the various aspects of immature B
cell differentiation described here, in particular, in the reg-
ulation of Ig   expression. Our cell culture studies using
chemical inhibitors suggest that a Src-family tyrosine kinase
and phosphoinositide 3-kinase (PI3K) are involved in the
latter aspect (Fig. 6). It is reasonable to assume that a Src
family tyrosine kinase is involved as Lyn is proximal to
BCR signaling and together with Syk, initiates the whole
cascade of BCR signal transduction (2, 4). The role of
PI3K is far less clear although incidentally, PI3K /  mice
(35, 36) have similar defects compared with BLNK / 
mice (13–16). PI3K is activated upon BCR stimulation and
generates lipid products that recruit Btk and phospholipase
C- 2 (PLC 2) to the plasma membrane (37, 38). As
BLNK is part of the B cell “signalosome” that also includes
Btk and PLC 2 (37, 38), it will be interesting to determine
if Btk /  (31, 32), PLC 2 /  (39, 40), and PI3K /  (35,
36) mice bearing transgenic BCR also have similar defects
in Ig   expression and immature B cell differentiation.
These experiments are currently underway. Last but not
least, as a note of precaution, our inhibition studies in no
way rule out the involvement of other signaling pathways,
in particular that of NF- B signaling and Ca2  fluxes, in
the regulation of   light chain expression and much work
remains to be done in these aspects.
The finding that the majority of the peripheral B cells in
TG1 BLNK /  mice are blocked at the transitional B cell
stage is also intriguing (Fig. 8). Presumably, BCR signaling
involving BLNK may be required for T1 cells to differenti-
ate into T2 cells and later, enter the long-lived mature B
cell pool. Many other mutations that affect BCR signaling,
for example those of Ig , Btk, Syk, and CD45, have also
been shown to interfere with transitional B cell maturation
(27). However, the exact mechanism that regulates transi-
tional to mature B cell differentiation remains to be deter-
mined. Recently, it has been shown that T2 cells can be
distinguished from T1 cells by their ability to up-regulate
the cell survival Bcl-xL and cell cycle cyclin D2 proteins
upon BCR stimulation (28). We have previously shown
that BLNK-deficient B cells do not up-regulate these cell
survival and cell cycle proteins and have a defect in NF- B
signaling (12). Thus, basal or induced NF- B signaling may
be required for the differentiation of transitional B cells.
Consistent with this argument, mice lacking I B kinase  
and therefore unable to activate NF- B signaling do not
generate mature B cells (41).
In conclusion, the data presented in this paper indicate
that the adaptor protein BLNK plays a critical role in im-
mature and transitional B cell differentiation. Although
BLNK may be involved in signaling by other cell surface
receptors, the phenotype described here is more consistent
with its role in BCR signal transduction. Our data would
suggest that once the BCR is assemble in immature B cell,
it is capable of signaling and the signals regulate both the
increased production of Ig light chains at the transcriptional
level as well as the continued cellular maturation of lym-
phocytes. Elucidation of the signaling pathways associated
with BLNK may shed light on how these processes are reg-
ulated.
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